Adults 18 to 71, any sex, with Multiple Sclerosis or Cognitive Decline. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change in Processing Speed After 6 Weeks of Treatment With a Digital Therapeutic 'Game 1', vs. 'Game 2'.Primary· Baseline and 6 weeks
Processing speed is being measured by the Symbol Digit Modalities Test (SDMT) score. SDMT measures the time to pair abstract symbols with specific numbers. The test requires visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items in 90 seconds. (max=110, min=0). Higher scores indicate improvement. Lower scores indicate worsening.
Group
Value
95% CI
AKL-T03
6.10
± 4.62
AKL-T09
3.55
± 7.51
Number of Participants With at Least 4-point Increase in SDMT Above Their Baseline Value 8 Weeks After TreatmentSecondary· 14 weeks
Number of participants showing a clinically meaningful 4+ point increase in SDMT (symbol digit modalities test) relative to baseline SDMT score. Comparison of SDMT changes 8 weeks after end of treatment with Tool 1 vs. Tool 2.
Group
Value
95% CI
AKL-T03
14
AKL-T09
7
Change in Mood After 6 Weeks Treatment With Game 1 vs. Game 2Secondary· Baseline and 6 weeks
Comparison of changes in mood (depression, anxiety). Depression measured using the Center for Epidemiologic Studies Depression Scale (CES-D). Possible range of scores is zero to 60, with the higher scores indicating the presence of more symptomatology. Anxiety measured using the State-Trait Anxiety Inventory - State subtest (STAI-S) and the State-Trait Anxiety Inventory - Trait subtest (STAI-T). Both have 20 questions and a score range 20-80, with higher scores indicating greater anxiety.
Depression (CES-D)
Group
Value
95% CI
AKL-T03
1.11
± 6.14
AKL-T09
-.90
± 5.57
Anxiety - State (STAI-S)
Group
Value
95% CI
AKL-T03
.05
± 4.64
AKL-T09
.21
± 8.93
Anxiety - Trait (STAI-T)
Group
Value
95% CI
AKL-T03
.77
± 4.10
AKL-T09
.35
± 3.35
Change in Fatigue After 6 Weeks Treatment With Game 1 vs. Game 2.Secondary· Baseline and 6 weeks
Fatigue is being measured by the Modified Fatigue Impact Scale (MFIS) which has participants rank 21 items on 1 to 4 (never to always) scale. The score is the sum of these subscales. (max=84, min=0) Lower scores indicate improvement. Higher scores indicate worsening.
Group
Value
95% CI
AKL-T03
-4.79
± 6.27
AKL-T09
-2.95
± 9.55
Change in a Digital Cognitive Battery After 6 Weeks Treatment With Game 1 vs. Game 2.Secondary· Baseline and 6 weeks
Comparison of changes in scores on Match, a tablet-based assessment of processing speed and executive function. Performance is gauged on a continuous scale using the total number of correct responses given in 2-minutes. The minimum possible score is 0 (no correct responses) with higher scores indicating better performance (no maximum possible score).
Group
Value
95% CI
AKL-T03
0.94
± 3.54
AKL-T09
0.35
± 4.66
Change in Paper and Pencil Cognitive Testing After 6 Weeks Treatment With Game 1 vs. Game 2.Secondary· Baseline and 6 weeks
Comparison of changes in cognition, as assessed using the BICAMS battery (Brief International Cognitive Assessment for Multiple Sclerosis) and PASAT (Paced Auditory Serial Addition Test). The BICAMS battery is composed of 3 tests (for all, higher scores indicate better performance): (1) The Symbol Digit Modalities Test (SDMT), a measure of information processing speed where performance is gauged by the number of correct responses given in 90-seconds, with a minimum possible score of 0 and maximum of 110. (2) The California Verbal Learning Test-II (CVLT-II) is a 5-trial auditory/verbal learning
SDMT
Group
Value
95% CI
AKL-T03
6.10
± 4.62
AKL-T09
3.55
± 7.51
CVLT-II
Group
Value
95% CI
AKL-T03
2.05
± 9.14
AKL-T09
5.20
± 8.60
BVMT-R
Group
Value
95% CI
AKL-T03
0.70
± 4.47
AKL-T09
3.25
± 5.23
PASAT
Group
Value
95% CI
AKL-T03
2.72
± 5.41
AKL-T09
2.53
± 7.19
Sponsor's own description
A DIGITAL THERAPEUTIC TO IMPROVE THINKING IN MULTIPLE SCLEROSIS
WHO: 65 participants with a confirmed diagnosis of Multiple Sclerosis (MS)
WHY: Purpose of the study is to compare the effect of 2 tablet-based brain training digital tools on important components of thinking (cognition).
WHAT: Complete a set of tests (physical and cognitive) at baseline, 6 weeks and 14 weeks, and use one of two brain training tools on an iPad in your home, for 25 minutes a day, 5 days a week, for 6 weeks.
WHERE: UCSF WEILL INSTITUTE FOR NEUROSCIENCES (675 Nelson Rising Lane, San Francisco, CA)
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal
· NA
· recruiting
NCT07524231 — Evaluation of the Effects of Laughter Yoga
· NA
· recruiting
NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS
· recruiting
NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity
· recruiting
NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS
· NA
· recruiting
Other University of California, San Francisco trials
Trials by the same sponsor.
NCT05284773 — Screening for Acute Malnutrition
· NA
· withdrawn
NCT04634851 — Video Home Visits for Dietary Counselling
· NA
· not yet recruiting
NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M
· Phase 1, PHASE2
· not yet recruiting
NCT07534098 — Intervention for Hearing Health Among Native Americans
· NA
· not yet recruiting
NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT)
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
Last refreshed: 26 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03569618.